Kuvan
Phase 2Small molecule
BioMarin PharmaceuticalKuvan is one of 189 small molecule programs targeting Schizoaffective Disorder. It is currently in Phase 2.
6
Indications
16
Total Trials
0
Active Trials
188
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Kuvan
BioMarin PharmaceuticalPhase 2
Bayer Aspirin
BayerPreclinical
LCZ696
NovartisPreclinical
Activase
RochePreclinical
Zemplar
AbbViePreclinical
Zoloft
VViatris Specialty LLC
Preclinical
Tamiflu
CConrado Roberto Hoffmann Filho
Preclinical
Coumadin
AAbbott
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Phenylketonuria7 trials
Show 4 more trials
5 more indications
Pilot Study1 trial
A Pilot Study on Diurnal Variation
Terminated·—·N/A·NCT01806051·6 enrolled
Heart Failure1 trial
Rhode Island Diastolic Dysfunction - Heart Failure
Completed·—·N/A·NCT02353312·28 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Kuvan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company